Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.

摘要: Purpose: KRAS mutations are identified in approximately 30% of patients with non–small cell lung cancer (NSCLC). Novel direct inhibitors G12C have shown activity early-phase clinical trials. We hypothesized that may distinct characteristics and responses to therapies. Experimental Design: Through routine next-generation sequencing, we KRAS-mutant NSCLC treated at Memorial Sloan Kettering Cancer Center (New York, NY) from 2014 2018 reviewed tumor characteristics, overall survival, treatment outcomes. Results: 1,194 NSCLC, including 770 recurrent or metastatic disease. were present 46% non-G12C 54%. Patients had a higher mutation burden (median, 8.8 vs. 7 mut/Mb; P = 0.006) median PD-L1 expression (5% 1%). The comutation patterns STK11 (28% 29%) KEAP1 (23% 24%) similar. survivals diagnosis similar for (13.4 months) (13.1 months; 0.96). In ≥50%, there was not significant difference response rate single-agent immune checkpoint inhibitor (40% 58%; 0.07). Conclusions: provide outcome data large series G12C–mutant available therapies, demonstrating duration benefit therapies those seen mutations. Strategies incorporate new targeted into the current paradigm will need consider outcomes specific harboring